Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 5018 results found since Jan 2013.
Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology
DISCUSSION: The panel achieved broad consensus on issues related to how to treat children with newly diagnosed ITP, providing a comprehensive review of all relevant clinical aspects.PMID:37677093 | DOI:10.2450/BloodTransfus.501
Source: Blood Transfusion - September 7, 2023 Category: Hematology Authors: Giovanna Russo Emilia Parodi Piero Farruggia Lucia D Notarangelo Silverio Perrotta Maddalena Casale Simone Cesaro Giovanni Del Borrello Giovanni C Del Vecchio Fiorina Giona Chiara Gorio Saverio Ladogana Giuseppe Lassandro Antonio Marzollo Karolina Maslak Source Type: research
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review
CONCLUSIONS: The use of SC daratumumab, rituximab, and trastuzumab in patients with cancer reduces direct and indirect costs and adverse events compared to IV use. Patients prefer the SC administration, perceiving more comfort, and less pain at the administration site.PMID:37665685 | DOI:10.1080/14737167.2023.2249232
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 4, 2023 Category: Health Management Authors: Ana Parra Claudia Hern ández Laura Prieto-Pinto Source Type: research
Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation
In conclusion, the male sex, high actual body weight, BSA, and BMI may be new predictive markers for rituximab-induced IRRs in renal transplant recipients. Therefore, clinicians should carefully monitor patients who receive rituximab before renal transplantation and present with the predictive markers.PMID:37661411 | DOI:10.1248/bpb.b23-00157
Source: Biological and Pharmaceutical Bulletin - September 4, 2023 Category: Drugs & Pharmacology Authors: Hironobu Nishiura Masaya Takahashi Tomoaki Iwai Junji Uchida Yasutaka Nakamura Source Type: research
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review
CONCLUSIONS: The use of SC daratumumab, rituximab, and trastuzumab in patients with cancer reduces direct and indirect costs and adverse events compared to IV use. Patients prefer the SC administration, perceiving more comfort, and less pain at the administration site.PMID:37665685 | DOI:10.1080/14737167.2023.2249232
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 4, 2023 Category: Health Management Authors: Ana Parra Claudia Hern ández Laura Prieto-Pinto Source Type: research
Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation
In conclusion, the male sex, high actual body weight, BSA, and BMI may be new predictive markers for rituximab-induced IRRs in renal transplant recipients. Therefore, clinicians should carefully monitor patients who receive rituximab before renal transplantation and present with the predictive markers.PMID:37661411 | DOI:10.1248/bpb.b23-00157
Source: Biological and Pharmaceutical Bulletin - September 4, 2023 Category: Drugs & Pharmacology Authors: Hironobu Nishiura Masaya Takahashi Tomoaki Iwai Junji Uchida Yasutaka Nakamura Source Type: research
